Exploring the plasmatic platelet-activating factor acetylhydrolase activity in patients with anti-phospholipid antibodies

@inproceedings{Fabris2017ExploringTP,
  title={Exploring the plasmatic platelet-activating factor acetylhydrolase activity in patients with anti-phospholipid antibodies},
  author={Martina Fabris and Adriana Cif{\`u} and Cinzia Pistis and Massimo Siega-Ducaton and Desr{\'e} Ethel Fontana and Roberta Giacomello and Elio Tonutti and Francesco Curcio},
  booktitle={Autoimmunity Highlights},
  year={2017}
}
To explore the role of plasmatic platelet-activating factor acetylhydrolase (PAF-AH), a marker of cardiovascular risk, in patients with anti-phospholipid antibodies (aPL). PAF-AH activity was assessed in a series of 167 unselected patients screened for aPL in a context of thrombotic events, risk of thrombosis or obstetric complications and in 77 blood donors. 116/167 patients showed positive results for at least one aPL among IgG/IgM anti-prothrombin/phosphatidylserine (aPS/PT), anti… CONTINUE READING

Citations

Publications citing this paper.

References

Publications referenced by this paper.
Showing 1-10 of 29 references

Tall AR (2016) Atherosclerosis: successes, surprises, and future challenges

  • P Libby, KE Bornfeldt
  • Circ Res
  • 2016
1 Excerpt

Similar Papers

Loading similar papers…